Abstract: A compound of formula (I) useful in the treatment of a herpes viral infection. A pharmaceutical composition including the compound of formula (I).
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Applicant:
VIRONOVA HERPES AB
Inventors:
Mohammed HOMMAN, Ngarita KINGI, Jan BERGMAN, Robert BERG
Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
Type:
Application
Filed:
March 14, 2013
Publication date:
February 4, 2016
Inventors:
Dorre A. GRUENEBERG, Ori KALID, Jun XIAN, Sharanappa B. RAJUR, Hwa-ok KIM, Venugopal Rao NEELAGIRI, Paresh GAONKAR, Divakaramenon MADHAVAN, Chaeho MOON, Madhavi NEELAGIRI
Abstract: Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Type:
Application
Filed:
July 31, 2015
Publication date:
February 4, 2016
Inventors:
Wei Chen, Longcheng Wang, Zhaozhong J. Jia
Abstract: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.
Type:
Application
Filed:
October 12, 2015
Publication date:
February 4, 2016
Inventors:
Erin M. Duffy, Ashoke Bhattacharjee, Hardwin O'Dowd, Marco DeVivo, Zoltan F. Kanyo, Jacek G. Martinow, Ik-Hyeon Paik, Matthew H. Scheideman, Sandra Sinishtaj, Brian T. Wimberly, Yusheng Wu
Abstract: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
Type:
Application
Filed:
October 13, 2015
Publication date:
February 4, 2016
Inventors:
Scott A. Mitchell, Kevin S. Currie, Peter A. Blomgren, Jeffrey E. Kropf, Seung H. Lee, Jianjun Xu, Douglas G. Stafford, James P. Harding, Antonio J.M. Barbosa, JR., Zhongdong Zhao, David M. Armistead, Soumya Mitra
Abstract: Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Type:
Application
Filed:
June 4, 2015
Publication date:
February 4, 2016
Inventors:
Peng LI, Hailin ZHENG, Jun ZHAO, Lawrence P. WENNOGLE
Abstract: Stable crystalline forms of a compound represented by the formula (IA): , an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.
Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.
Type:
Application
Filed:
August 3, 2015
Publication date:
February 4, 2016
Applicant:
SALIX PHARMACEUTICALS, LTD
Inventors:
Stephan D. Parent, Lisa Lynn McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared Peters Smit
Abstract: Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediated by K-Ras, H-Ras or N-ras G12C.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Inventors:
Pingda Ren, Yi Liu, Liansheng Li, Jun Feng
Abstract: Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
Type:
Application
Filed:
February 27, 2014
Publication date:
February 4, 2016
Inventors:
Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
Abstract: Discloses is a process for preparation of a compound of formula 7, or a derivative thereof, wherein PG1 is an alcohol protecting group. Also, disclosed are intermediates and processes for their preparation. The compound of formula 7 can be useful in the preparation of halinchondrin analogs such as Eribulin.
Type:
Application
Filed:
October 14, 2015
Publication date:
February 4, 2016
Inventors:
Fabio E.S. SOUZA, Jason A. BEXRUD, Ricardo ORPRECIO, Boris GORIN
Abstract: Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.
Type:
Application
Filed:
June 18, 2013
Publication date:
February 4, 2016
Inventors:
Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers
Abstract: The invention relates to novel maytansinoid compounds having sulfoxide linkers and more specifically to novel maytansinoid compounds of structural formula (I) and (II). The invention also provides conjugates of the maytansinoid compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Applicant:
IRONWOOD PHARMACEUTICALS, INC.
Inventors:
Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, Rajesh R. IYENGAR, Ara MERMERIAN, G-Yoon Jamie IM, Thomas Wai-Ho LEE, Colleen HUDSON, Glen Robert RENNIE, James JIA, Paul Allan RENHOWE, Timothy Claude BARDEN, Xiang Y. YU, James Edward SHEPPECK, Karthik IYER, Joon JUNG, George Todd MILNE, Kimberly Kafadar LONG
Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Type:
Application
Filed:
March 10, 2014
Publication date:
February 4, 2016
Applicant:
GLOBAL BLOOD THERAPEUTICS, INC.
Inventors:
Zhe LI, Qing XU, Brian W. METCALF, Stephen L. GWALTNEY, II, Jason R. HARRIS, Calvin W. YEE
Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 kinase, for use in the diagnosis, prevention and/or treatment of LRRK2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent. Finally, the present invention also relates to new macrocyclic compounds.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Inventors:
Jan HOFLACK, Petra BLOM, Olivier LAVERGNE
Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making betalactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
Abstract: The present invention relates to compounds of Formula (I), wherein the variables are as defined herein. Pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof are disclosed.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Inventors:
John Emmerson Campbell, Kevin Wayne Kuntz
Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.
Type:
Application
Filed:
March 10, 2015
Publication date:
February 4, 2016
Inventors:
Jay R. LULY, Yoshisuke NAKASATO, Etsuo OHSHIMA, Geraldine C.B. HARRIMAN, Kenneth G. CARSON, Shomir GHOSH, Amy M. ELDER, Karen M. MATTIA
Abstract: Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or radiation.
Type:
Application
Filed:
March 6, 2014
Publication date:
February 4, 2016
Inventors:
Evan R. Trivedi, Emily A. Waters, Anthony G.M. Barrett, Brian M. Hoffman, Thomas J. Meade
Abstract: The present invention relates to luminescent lanthanide complexes including a chelating agent, formed with a macrocycle or a set of ligands, complexing a lanthanide ion Ln3+, wherein the chelating agent is substituted with at least two groups. The invention is most particularly applied to lanthanide complexes, the chelating agent of which is formed the with three ligands integrating a 2,6 pyridine-di(carboxylic acid) or is formed with a macrocycle having a 1,4,7 triazacyclononane structure.
Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
Type:
Application
Filed:
December 29, 2014
Publication date:
February 4, 2016
Inventors:
Keith V. Wood, Georgyi V. Los, Robert F. Bulleit, Dieter Klaubert, Mark McDougall, Chad Zimprich
Abstract: The present invention relates to novel cluster boron compounds and their use as sodium channel blockers. The invention also provides methods for making and using the compounds.
Type:
Application
Filed:
August 18, 2015
Publication date:
February 4, 2016
Applicant:
THE CURATORS OF THE UNIVERSITY OF MISSOURI
Inventors:
George R. Kracke, Yulia Sevryugina, Marion Frederick Hawthorne
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Type:
Application
Filed:
October 12, 2015
Publication date:
February 4, 2016
Inventors:
Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar-Lay, Debra L. Mazaik, Quentin J. Mccubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad Varga, Peter N. Zawaneh
Abstract: Thermal conductive compositions, methods for their preparation, and use are provided, which include, for example, as thermal sinks and other uses.
Type:
Application
Filed:
July 31, 2014
Publication date:
February 4, 2016
Inventors:
Georgius Abidal ADAM, Mordehai MARGALIT, Bradley Kirk ROBERTS, Feng WAN
Abstract: A polymer material comprising a constraint bicyclic bridged structure such as bicyclo(2,2,1) ring system, most preferably a norbornyl group, pendant to a siloxane backbone. The bridged bicyclic-containing materials can exhibit good refractive index, transparency, gas permeability, and/or other properties making them suitable for use in a variety of applications.
Abstract: Provided are silacyclopropane-based compounds and methods of making the same. Also provided are methods of using said compounds in film deposition processes to deposit films comprising silicon. Certain methods comprise exposing a substrate surface to a silacyclopropane-based precursor and a co-reagent in various combinations.
Abstract: A method of making a diakyl-, diaryl-, or alkylaryl-dihalosilane in a Grignard coupling reaction with a high degree of selectivity is provided. More specifically, a Grignard reagent comprising an alkyl- or aryl-magnesium halide is allowed to react with an alkyl- or aryl-trihalosilane precursor or reagent to produce a product mixture of R2SiX2 and R3SiX, wherein each R is independently selected to be an alkyl or aryl group and X is a halogen group, such that the R2SiX2 product is formed with a high degree of selectivity. High selectivity is defined as the mass ratio of R2SiX2 product to the R3SiX product that is formed in the reaction being greater than 7:1.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Applicant:
DOW CORNING CORPORATION
Inventors:
James LEE, Binh Thanh NGUYEN, Scott E. PIDER, Steven L. UMPHREY, Hanh Xuan VO
Abstract: The present invention provides a new photoreactive compound which can be used in technologies for photoreactions of nucleic acid, and also provides a photoreactive crosslinking agent comprising the above photoreactive compound. A photoreactive compound represented by the following formula I can be used.
Type:
Application
Filed:
March 27, 2014
Publication date:
February 4, 2016
Applicant:
JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: Atomic layer deposition (ALD) processes for forming Te-containing thin films, such as Sb—Te, Ge—Te, Ge—Sb—Te, Bi—Te, and Zn—Te thin films are provided. ALD processes are also provided for forming Se-containing thin films, such as Sb—Se, Ge—Se, Ge—Sb—Se, Bi—Se, and Zn—Se thin films are also provided. Te and Se precursors of the formula (Te,Se)(SiR1R2R3)2 are preferably used, wherein R1, R2, and R3 are alkyl groups. Methods are also provided for synthesizing these Te and Se precursors. Methods are also provided for using the Te and Se thin films in phase change memory devices.
Type:
Application
Filed:
October 13, 2015
Publication date:
February 4, 2016
Inventors:
Viljami Pore, Timo Hatanpaa, Mikko Ritala, Markku Leskelä
Abstract: An imidazolate framework material comprises a general structure, M1-IM-M2, wherein IM is an imidazolate or a substituted imidazolate linking moiety, such as a 4,5-dicyanoimidazolate or a hydrolyzed or substituted 4,5 dicyanoimidazolate linking moiety, wherein M1 and M2 comprise the same or different metal cations, wherein at least one of M1 and M2 comprises a trivalent metal cation and wherein neither M1 nor M2 comprises a monovalent cation.
Type:
Application
Filed:
June 11, 2015
Publication date:
February 4, 2016
Applicant:
EXXONMOBIL RESEARCH AND ENGINEERING COMPANY
Inventors:
Partha Nandi, Mobae Afeworki, Quddus Nizami, Simon C. Weston
Abstract: An oxygen assisted Organosolv process for a more efficient delignification and producing bio-products by decomposing lignocellulosic materials comprises providing a lignin solvent with water, an acid, an oxidant and one or more lignin dissolving chemicals. The process also includes placing biomass in contact with oxidant, acid, water, the lignin solvent in any order or combined to form a recyclable solvent, and recycling at least a portion of the recyclable solvent by circulating the recyclable solvent back into contact with the biomass. The circulating of the recyclable solvent occurs for a period of time, during which, acid and oxidant may be added if necessary as they may be consumed by the process, after which, the process then includes separating material such as chemicals and lignin from the recyclable solvent.
Type:
Application
Filed:
August 1, 2014
Publication date:
February 4, 2016
Applicant:
American Science and Technology Corporation
Inventors:
Ali Manesh, John H. Guenther, Edwin G. Zoborowski, Walter Braenner, Mohammad Ali Manesh, Lee J. Hawk
Abstract: Methods and composition for nucleic acid isolation are provided. In one embodiment, the invention provides a method for nucleic acid purification from biological samples extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for differential isolation of RNA and DNA.
Abstract: The present invention relates to glycoside-derived compounds, to the processes for preparing same and to the use thereof as prosthetic groups for radiolabelling biomolecules. These compounds are co-azido-alkyl 6-deoxy-6-[18F]-fluoroglycosides of formula (I), in which: k is equal to 2 or 3; n is an integer between 1 and 5; R is independently H or a C1-C5 alkyl group, m being an integer between 0 and 2 if k=2 and m between 0 and 3 if k=3; and X is chosen from the group comprising O, S, CH2 and NR?, in which R? is independently a C1-C5 alkyl group or an aryl group, including all the stereoisomers thereof.
Type:
Application
Filed:
July 2, 2013
Publication date:
February 4, 2016
Applicants:
UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
Inventors:
YVES CHAPLEUR, Sandrine LAMANDE, Charlotte COLLET, Françoise CHRETIEN
Abstract: Methods for purifying steviol glycosides, including Rebaudioside X, are provided herein. Sweetener and sweetened containing Rebaudioside X are also provided herein. Methods of improving the flavor and/or temporal profile of sweetenable compositions, such as beverages, are also provided.
Type:
Application
Filed:
December 19, 2012
Publication date:
February 4, 2016
Inventors:
Indra Prakash, Avetik Markosyan, Sai Prakash Venkata Chaturvedulla, Mary Campbell, Rafael San Miguel, Siddhartha Purkayastha, Marquita Johnson
Abstract: The invention provides molecules, which are based on a modification of azithromycin, removing the antibiotic effect, while retaining other beneficial effects, such as, but not limited to immunomodulatory effects. The compounds of the invention can be described by compounds of Formula (I) as further defined herein.
Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
Type:
Application
Filed:
March 18, 2015
Publication date:
February 4, 2016
Inventors:
Ashoke Bhattacharjee, Zoltan F. Kanyo, Edward C. Sherer
Abstract: Compounds of the general formula 1, stereoisomers, pharmaceutically acceptable salts, and/or hydrates, solvates or crystalline forms thereof wherein R1 represents C1-C4 alkyl; R2 and R3 represents fluoro, or R2 represents fluoro, and R3 represents methyl; R4 and R5 represents hydrogen, or R4 represents C1-C6 acyl, and R5 represents hydrogen, or R4 represents hydrogen, and R5 represents C1-C6 acyl, or R4 represents optionally substituted ?-aminoacyl, and R5 represents hydrogen, or R4 represents hydrogen, and R5 represents optionally substituted ?-aminoacyl; R6 represents hydrogen, methyl, methoxy or halogen.
Abstract: Disclosed are messenger RNA molecules and related compositions incorporating a 4?-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4?-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.
Abstract: Compounds according to formula I or II are provided. Such compounds are useful in treating cancers, such as leukemia, colon cancer, breast cancer, or prostate cancer by beneficially inhibiting CYP17A1. Pharmaceutical compositions and methods including the compounds are also provided.
Type:
Application
Filed:
July 31, 2015
Publication date:
February 4, 2016
Inventors:
Jeffrey Aube, Emily E. Scott, Charlie Fehl
Abstract: (3alpha,3beta)-disubstituted 17beta steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.
Type:
Application
Filed:
March 13, 2014
Publication date:
February 4, 2016
Inventors:
Gabriel Martinez Botella, Boyd L. Harrison, Albert J. Robichaud, Francesco G. Salituro
Abstract: Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis.
Type:
Application
Filed:
February 24, 2014
Publication date:
February 4, 2016
Applicant:
Massachusetts Institute of Technology
Inventors:
Mark David Simon, Bradley L. Pentelute, Andrea Adamo, Patrick Louis Heider, Klavs F. Jensen
Abstract: Provided is a method of refolding of recombinant GCSF that minimizes the generation of oxidized forms of GCSF by optimizing the refolding of inclusion bodies containing recombinant GCSF.
Abstract: The presently disclosed and/or claimed inventive concept(s) relates generally to processes for the non-aqueous hydrolysis of proteins and/or protein-containing materials and, more particularly but without limitation, to methods for producing amino acids from the non-aqueous solid acid hydrolysis of proteins and/or protein-containing materials. More particularly, but without limitation, the methods disclosed herein for producing amino acids from the solid acid hydrolysis of proteins and/or protein-containing materials are performed in a non-aqueous/solvent-free process. In one particular embodiment, the process of producing such amino acids from proteins and/or protein-containing materials includes, without limitation, the step of mechanocatalytically reacting a solid acid with one or more proteins and/or protein containing materials in a non-aqueous/solvent-free process using the solid acid as a catalyst.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Applicant:
University of Central Florida Research Foundation, Inc.
Abstract: Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Inventors:
Dustin McMinn, Henry Johnson, David C. Moebius
Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or racemic mixture or stereoisomer thereof, and methods for preventing or treating an LDL-cholesterol-related disease or disorder using such compound(s), and kits and compositions comprising such compound(s).
Type:
Application
Filed:
March 14, 2014
Publication date:
February 4, 2016
Inventors:
DANIEL GUAY, SHELDON CRANE, NICOLAS LACHANCE, JEAN-FRANCOIS CHIASSON, VOUY LINH TRUONG, PATRICK LACOMBE, KATHRYN SKOREY, NABIL G. SEIDAH
Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.
Abstract: This invention relates to neural regeneration peptides (NRPs), including NRP-2945, NRP-2983 and NNZ-4921, as well as the receptors that have been newly identified as interacting with these NRPs, such as CXCR4 in collaboration with CCR3. The invention further relates to methods of using these NRPs and its respective chemokine receptors, as well as compositions comprising such components.
Abstract: Provided is a peptide including X2SX1AAX2X3P (SEQ ID NO. 1), X2X2PX3X2AX3P (SEQ ID NO. 2), SX1AAX2X3P (SEQ ID NO. 3), or X2PX3X2AX3P (SEQ ID NO. 4), which bind to graphitic materials or volatile organic compounds.
Type:
Application
Filed:
July 7, 2015
Publication date:
February 4, 2016
Inventors:
Hyunjung YI, Ki Young LEE, Chaun JANG, Joonyeon CHANG, Sang Kyung KIM, Soomi JU